US biotech Gilead Sciences (Nasdaq: GILD) has agreed a global licensing deal worth up to $1.5 billion with China’s Genhouse Bio for its synthetic lethal cancer candidate GH31.
Driving Innovation and Sustainability in the Sanitary Napkin Market with Advanced Manufacturing Solutions CALIFORNIA, ...
HANGZHOU CITY, ZHEJIANG PROVINCE, CHINA, February 10, 2026 /EINPresswire.com/ -- The shape moulding machine industry ...
The new product offering will supply global life science researchers with performance and reliability in multi-fragment ...
SEOUL, 서울 – SEOUL, SOUTH KOREA, January 28, 2026 / EINPresswire.com / — LEESOL, a South Korea–based sleep and mental wellness technology company, announced today that its sleep and mental health ...
Agreement integrates Clyde Biosciences' human-relevant, CellOPTIQ cardiotoxicity screen for chemical safety assessment ...
How environmentally responsible businesses can demonstrate proof of impact to their stakeholders LONDON, UNITED ...
The U.S. National Science Foundation (NSF) announced on February 13, 2026, that it is investing up to $100 million to ...
Cells constantly monitor and recycle their proteins through a tightly regulated waste-disposal system. Proteins that are no ...
NANJING, JIANGSU, CHINA, February 6, 2026 /EINPresswire.com/ -- The crisp mountain air calls for gear that respects the ...
Based on these challenges, a comprehensive reassessment of how AI should be deployed in electrocatalysis has become urgently needed. Addressing this need, a review published (DOI: 10.1016/j.esci.2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results